Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.…
Niagen Bioscience to Present at the Sixth Annual Longevity Summit Taking Place at the Buck Institute for Research on Aging
Niagen Bioscience (NASDAQ: NAGE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Packaged Foods industry, part of the Consumer Defensive sector, and reports about 117 employees.
The shares were at 1.840 USD on 20 November 2026, down 73.1% over 52 weeks. Its 52-week range is 1.790 USD to 7.280 USD: the price is 74.7% below the high and 2.8% above the low.
At a market capitalisation of 145.72M USD, it trades at 15.3 times trailing earnings. The median trailing P/E of its 18 largest Packaged Foods peers is 24.8, a discount of 38% for NAGE.
Niagen Bioscience reports return on equity of 22.7%, an operating margin of 2.3% and revenue down 20.0% year over year.
It holds more cash than debt, a net cash position of 67.28M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 3 March 2027.